Investigating exosomal ACE2 for treating COVID-19
Clinical analysis and therapeutic development of exosomal ACE2
This study is looking at a protein in the blood of COVID-19 patients to see if it can help create new treatments and tests that identify people at risk for severe illness, with the hope of blocking the virus from entering cells and preventing infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10888159 on NIH RePORTER |
What this research studies
This research focuses on understanding how exosomal ACE2, a protein found in the blood of COVID-19 patients, can be used to develop new treatments for the disease. By analyzing the levels of ACE2 in exosomes, the researchers aim to create a clinical assay that can help identify patients at risk for severe COVID-19. Additionally, they are exploring the potential of exosomal ACE2 as a therapeutic agent that could block the virus from entering cells, thereby preventing infection. This innovative approach seeks to address the challenges posed by current and future strains of coronaviruses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with COVID-19, particularly those experiencing severe symptoms or at high risk for complications.
Not a fit: Patients who have not been infected with COVID-19 or those with mild symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with COVID-19 and potentially other coronavirus infections.
How similar studies have performed: Other research has shown promise in using biomarkers for treatment strategies in viral infections, making this approach both innovative and grounded in prior success.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Liu, Huiping — Northwestern University at Chicago
- Study coordinator: Liu, Huiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.